Journal of Clinical Pathways April 12, 2022
Numinus Wellness has entered into an agreement to acquire Novamind in a $26.2 million ($20.77 million US) deal announced by the 2 companies on Tuesday morning.
The deal creates a network of 13 wellness clinics across the US and Canada that will offer psychedelic treatments for mental health conditions, including post-traumatic stress disorder (PTSD), COVID-19 burnout, depression, addiction, and eating disorders. Services will include ketamine-assisted psychotherapy (KAP), esketamine, transcranial magnetic stimulation (TMS), psychotherapy, group therapy, medication management, psychedelic palliative care, and neurological care.
The companies also noted in a release that Novamind’s US Drug Enforcement Administration Schedule 1 licenses for psilocybin research will complement Numinus’ Health Canada Controlled Drugs & Substances license to possess, produce, assemble, sell, export, deliver, research,...
Today's Sponsors
Today's Sponsor